Table 1 Characteristics of the included cohort studies
Study | Country | Ethnicity | Design | Patient characteristics | Sample size | Mean age years | MetS diagnosis | MetS at baseline n (%) | Follow-up duration years | Outcomes reported | Outcome validation | Variables adjusted | NOS |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Pasanisi [15] | Italy | Caucasians | PC | Postmenopausal BC women 1 y after surgey, not undergoing chemotherapy | 110 | 56.8 | NCEP-ATP III | 16 (14.5) | 5.5 | Recurrence (32) | Hospital records | Age, stage at diagnosis, HR status, current tamoxifen treatment, time between diagnosis and recruitment, serum testosterone | 7 |
Oh [19] | Korea | Asians | PC | Newly diagnosed BC women after surgery | 747 | 45.9 | AHA/NHLBI | 268 (35.9) | 5.2 | Recurrence (94) stratified by ER/PR status | Hospital records | Age, alcohol consumption, BMI, regional lymph node metastasis, tumor size, and chemotherapy | 9 |
Calip [17] | US | Caucasians (90%) | RC | BC women 4Â m after surgery | 4216 | 62.2 | NCEP-ATP III | 1011 (23.9) | 6.3 | Recurrence (415), BC-related death (259), and all-cause death (1096) | Hospital records | Age, stage at diagnosis, HR status, primary treatment, race, menopausal status | 8 |
Berrino [16] | Italy | Caucasians | RC | Stage I-III BC women after surgery | 2092 | 51.4 | IDF | 419 (20.0) | 2.8 | Recurrence (94) stratified by ER status (164) | Hospital records | Age, education, stage at diagnosis, and the HR status | 8 |
Fan [20] | China | Asians | RC | Stage I-III BC women | 1249 | 49 | AACE | 206 (16.5) | 6.6 | Recurrence (265) and all-cause death (242) by HR status | Hospital records | Age, stage at diagnosis, surgery model, radiotherapy, and chemotherapy regimens | 8 |
Muniz [21] | The US | Caucasians | RC | Stage I-II BC women with HR + , HER2- | 534 | 56 | NCEP-ATP III | 117 (22.0) | 4.4 | Recurrence (24) | Hospital records | Age and stage at diagnosis | 7 |
Simon [18] | The US | Caucasians (94%) | PC | Postmenopausal BC women | 8641 | 62.9 | AHA/NHLBI | 423 (4.9) | 11.3 | BC-related death (619), and all-cause death (2181) | Medical record review linkage to the National Death Index | Age, stage at diagnosis, treatment, HR status, other comorbidities | 8 |
Grybach [22] | Ukraine | Caucasians | RC | Stage I-III BC women | 202 | 51.2 | NCEP-ATP III | 94 (46.5) | 5 | All-cause death (44) stratified by age | Hospital records | Age, stage at diagnosis, and HR status | 7 |
Tong [23] | China | Asians | RC | HER2-positive BC women receiving neoadjuvant therapy | 101 | 50.9 | AHA/NHLBI | 29 (28.7) | 2.4 | Recurrence (15) | Hospital records | Age, stage at diagnosis, HR status, and treatments | 7 |